Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Leases (2024 - 2025)

Axsome Therapeutics' Capital Leases history spans 2 years, with the latest figure at $4.2 million for Q4 2025.

  • For Q4 2025, Capital Leases rose 42.92% year-over-year to $4.2 million; the TTM value through Dec 2025 reached $4.2 million, up 42.92%, while the annual FY2025 figure was $4.2 million, 42.92% up from the prior year.
  • Capital Leases for Q4 2025 was $4.2 million at Axsome Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Capital Leases topped out at $4.7 million in Q3 2025 and bottomed at $1.7 million in Q1 2024.